Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA and Barcelona, Spain.
Eur J Cancer. 2020 Aug;135:62-65. doi: 10.1016/j.ejca.2020.05.026. Epub 2020 Jun 4.
While confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with hosts provides a significant number of potential drug targets and the potential to repurpose drugs already tested in other diseases. Herein, we report the biological rationale of immune-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immunocompetence.
虽然全球已有超过 470 万人确诊感染致命的 2019 年冠状病毒病（COVID-19），但科学家们仍在努力开发疫苗和治疗方法，试图减缓大流行并减轻疾病的损害。尽管目前尚无针对 COVID-19 患者的有效治疗方法，也无法对其并发症进行有效管理，但关于严重急性呼吸综合征冠状病毒 2 及其与宿主相互作用的知识正在迅速扩展，为大量潜在的药物靶点提供了依据，并有可能重新利用已经在其他疾病中进行过测试的药物。在此，我们报告了免疫激活药物的生物学原理，并简要总结了文献数据，这些数据表明，免疫检查点抑制剂最近已在癌症治疗之外的领域进行了测试，以期恢复细胞免疫能力，具有潜在的治疗价值。
